The role of regorafenib in the treatment of metastatic colorectal cancer
Regorafenib is a multi-tyrosine kinase inhibitor, associated with the activity in metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors. Regorafenib application in patients with mCRC after exhausting all available drug therapies have resulted in statistically significant increase i...
Main Author: | A A Tryakin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2016-06-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/27080/pdf |
Similar Items
-
The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01) -
Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01) -
Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
by: M. I. Sekacheva, et al.
Published: (2020-11-01) -
Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01) -
Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)